% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • henryofchang Oct 12, 2013 11:30 PM Flag

    Nelotanserin, Eplivanserin, Volinanserin all failed. Guess which drug is next...

    I know lots of people have not only money invested in ACAD. But let's have an honest discussion about this, feelings aside. FDA has nothing to lose by granting fast track application, they gain an enormous amount of extra fees. Someone tell me I'm wrong and that I should keep my shares by showing the actual data presented in their clinical trials, not the company's press release. What a deceptive world we live in......

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You imply that Pima will fail then give a schizo line of reasoning for it.... Maybe you are in the wrong biz....schill just isn't you... Should at least have a half-way believable spin!!!

    • Your anti psychotic? Oh wait you said next, Then I must say your ED medicine, GL2ALL

    • I suspect as market drops on Monday will see more typing monkeys hired by shorts showing up here...

    • oh go away pls

    • If you don't want to invest in Acadia DON'T, nobody is begging you to buy shares. if you have shares and don't believe that the company has been honest and straight forward with their clinical trials then sell and quit your whining. Obviously there are More Professional doctors and health care experts who have seen the data and are ecstatic about the results. From the wording of your post you are saying the FDA is involved in some type of fraud involving Acadia. I think you had better be careful about what you are implying here.

      Sentiment: Strong Buy

    • ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
      SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results today from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting. The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported.

      Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant antipsychotic efficacy on the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. Dr. Cummings presented new data from the -020 Study showing highly significant improvements in all secondary efficacy measures, including the Clinical Global Impression Severity, or CGI-S, scale (p

      Sentiment: Strong Buy

30.30+0.86(+2.84%)Jun 27 4:00 PMEDT